Illumina v. Molecular Loop: Genomics Patent Case Transferred to Delaware in Just 54 Days
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Illumina Inc. v. Molecular Loop Biosciences Inc. |
| Case Number | 1:24-cv-11501 (D. Mass.) & D. Del. successor docket |
| Court | U.S. District Court for the District of Massachusetts (Transferred to D. Del.) |
| Duration | June 9, 2024 – August 2, 2024 54 days |
| Outcome | Procedural: Venue Transferred |
| Patents at Issue | |
| Accused Products | TruSight Oncology 500 ctDNA v2, VeriSeq NIPT Solution v2 assay |
Case Overview
The Parties
⚖️ Plaintiffs
Global market leader in DNA sequencing and array-based technologies with an extensive IP portfolio in genomics and non-invasive prenatal testing (NIPT).
🛡️ Defendant
Genomics company offering sequencing-based assay solutions, active in liquid biopsy and oncology sequencing markets.
The Patents at Issue
This case involved five U.S. patents asserted by Illumina, Inc. and Verinata Health, Inc., covering critical technologies in next-generation sequencing (NGS), non-invasive prenatal testing (NIPT) methodology, and circulating tumor DNA (ctDNA) detection. These patents are registered with the U.S. Patent and Trademark Office (USPTO).
- • US11768200B2 (App. No. US17/339527) — Sequencing chemistry
- • US11840730B1 (App. No. US16/952764) — Sequencing chemistry
- • US11041851B2 (App. No. US14/854629) — NIPT methodology
- • US9163281B2 (App. No. US13/081660) — ctDNA detection
- • US11041852B2 (App. No. US17/149504) — NIPT methodology
Developing a new genomics assay?
Check if your NGS or liquid biopsy product might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Massachusetts District Court did not issue a merits ruling. The case was terminated in Massachusetts upon transfer to the District of Delaware pursuant to the parties’ Joint Motion to Transfer Venue. No damages were awarded, no injunctive relief was granted or denied, and no findings on validity or infringement were made at this stage.
The case remains active — now repositioned in Delaware for substantive adjudication.
Key Legal Issues
The sole dispositive action in Massachusetts was procedural: a consent-based venue transfer. The joint nature of the motion is strategically significant, indicating that both parties reached an agreement that Delaware was the more appropriate forum, avoiding a contested transfer motion that could have delayed proceedings and created early adversarial friction. Under 28 U.S.C. § 1404(a), courts may transfer cases for convenience of the parties and witnesses, or in the interest of justice.
Delaware’s District Court handles a disproportionate share of U.S. patent litigation due to its extensive IP expertise, well-developed local patent rules, and highly regarded docket management for complex multi-patent cases.
Freedom to Operate (FTO) Analysis in Genomics
This case highlights critical IP risks in NGS and liquid biopsy. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this technology space
- See which companies are most active in genomics patents
- Understand claim construction patterns specific to NGS
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description (e.g., NGS assay, NIPT solution)
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
NGS and Liquid Biopsy Platforms
5 Asserted Patents
In genomics sequencing technology
Strategic Design-Arounds
Possible with FTO planning
✅ Key Takeaways
Joint venue transfer motions are efficient tools for repositioning complex cases without adversarial delay.
Search related case law →Portfolio assertions (5+ patents) are increasingly standard in genomics patent enforcement, maximizing leverage.
Explore portfolio analysis tools →Delaware remains the preferred forum for multi-patent biotech disputes; counsel should anticipate this in initial venue analysis.
Understand Delaware’s patent rules →Frequently Asked Questions
Five U.S. patents were asserted: US11768200B2, US11840730B1, US11041851B2, US9163281B2, and US11041852B2 — covering NGS, NIPT, and ctDNA detection technologies.
Both parties jointly moved for transfer under 28 U.S.C. § 1404(a). The court granted the motion on August 2, 2024, citing the parties’ agreement that Delaware was the more appropriate forum.
It reinforces Delaware’s dominance as the preferred venue for complex biotech IP disputes and signals active enforcement of Illumina’s sequencing patent portfolio against commercial competitors in liquid biopsy and NIPT markets.
Ready to Strengthen Your Genomics IP Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision in life sciences.
References
- PACER: U.S. District Court for the District of Massachusetts — Case No. 1:24-cv-11501
- U.S. Patent and Trademark Office — Patent Center
- Cornell Legal Information Institute — 28 U.S.C. § 1404(a)
- PatSnap — IP Intelligence Solutions for Life Sciences
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.